Beijing Hope Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China and facing the world. The main business is R&D, production and sales of APIs and APIs, import and export trade, R&D of new pharmaceutical preparations and new drug registration. We have an R&D center in Beijing, a pharmaceutical intermediate production base in Hebei and Zhejiang, and a GMP-certified API production base in Shandong.
*The following content is generated by AI and is for reference only.
Tacrolimus, chemically known as FK506, is a potent macrocyclic lactone immunosuppressant primarily utilized in organ transplantation to prevent rejection. Its molecular formula is C44H69NO10, and it carries the CAS registry number 104987-11-3. This compound was originally isolated from the soil bacterium *Streptomyces tsukubaensis* found in Japan. Structurally, Tacrolimus belongs to the class of calcineurin inhibitors, functioning by binding with high affinity to the intracellular protein FKBP12. This complex subsequently inhibits calcineurin phosphatase activity, which blocks the dephosphorylation and nuclear translocation of the transcription factor NF-AT. Consequently, the production of interleukin-2 and other cytokines essential for T-cell activation is suppressed, effectively halting the immune response against foreign tissues.
Clinically, Tacrolimus is most commonly prescribed as an ointment or topical solution for the management of moderate-to-severe atopic dermatitis (eczema) when conventional therapies fail, offering a non-steroidal alternative that minimizes skin thinning risks. In systemic applications, oral capsules and intravenous formulations are critical components of maintenance regimens following kidney, liver, or heart transplants. It is often used in combination with other agents like corticosteroids or mycophenolate mofetil to optimize graft survival rates. The drug exhibits significant bioavailability issues due to extensive first-pass metabolism via the cytochrome P450 3A4 enzyme system, necessitating careful therapeutic drug monitoring to avoid toxicity or subtherapeutic levels. Common adverse effects include nephrotoxicity, hypertension, tremors, and hyperglycemia, requiring vigilant patient management. Despite its narrow therapeutic index, Tacrolimus remains a cornerstone in modern transplant medicine and dermatology due to its superior efficacy compared to cyclosporine in many clinical scenarios. Its discovery revolutionized post-transplant care, significantly improving long-term graft survival and quality of life for millions of patients worldwide, establishing it as one of the most vital pharmaceutical agents in immunology today.